Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically or clinically confirmed diagnosis of advanced HCC.~2. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS): 0-1.~3. Adequate laboratory values/organ function tests.~Exclusion criteria:~1. Simultaneous or metachronous cancers.~2. Pericardial, ascites, or pleural effusion requiring drainage.~3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring treatment.~4. Malabsorption syndrome.~5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor.~6. Use of drugs known to inhibit cytochrome P3A4.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lenvatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).